Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Systematic Review
PubMed
31416571
DOI
10.1016/j.mrrev.2019.05.002
PII: S1383-5742(19)30008-0
Knihovny.cz E-resources
- Keywords
- Biomarker, Cancer, Cell-free DNA, Circulating-tumor DNA, Liquid biopsy,
- MeSH
- Humans MeSH
- Biomarkers, Tumor genetics MeSH
- Neoplasms diagnosis genetics pathology MeSH
- Prognosis MeSH
- Liquid Biopsy methods MeSH
- Cell-Free Nucleic Acids genetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Systematic Review MeSH
- Names of Substances
- Biomarkers, Tumor MeSH
- Cell-Free Nucleic Acids MeSH
The development of minimally invasive and low-cost assay enabling early diagnosis, treatment response and prognosis in cancer patients may provide a promising alternative to tumor biopsy. Circulating cell-free DNA (cfDNA) is probably the most promising tool among all components of liquid biopsy. This review includes studies exploring cfDNA as the diagnostic, prognostic or predictive biomarker for all types of cancer. In this article, we systematically reviewed the relevant literature from PubMed about cfDNA. All articles presented higher cfDNA concentration in cancer patients when compared with patients with benign disease or healthy individuals. Most of the articles showed a connection between cfDNA and prognosis. The presence of high cfDNA level in serum or plasma was associated with worse overall patient's survival. This review supports the idea that the cfDNA analysis represents a promising research area and hopefully in the future, could be applied as a new biomarker for cancer detection, prognosis determination and prediction of the response to therapy.
References provided by Crossref.org
Colorectal Adenomas-Genetics and Searching for New Molecular Screening Biomarkers
